CSIMarket Company Name, Ticker, Competitors, else..
 
Applied Therapeutics Inc   (NASDAQ: APLT)
 
Price: $0.1080 $0.00 4.651%
Day's High: $0.11 Week Perf: 16.76 %
Day's Low: $ 0.10 30 Day Perf: 7.89 %
Volume (M): 2,650,657 52 Wk High: $ 1.50
Volume (M$): $ 286 52 Wk Avg: $0.49
Open: $0.10 52 Wk Low: $0.09



 Market Capitalization (Millions $) 16
 Shares Outstanding (Millions) 146
 Employees 80
 Revenues (TTM) (Millions $) 1
 Net Income (TTM) (Millions $) -18
 Cash Flow (TTM) (Millions $) -87
 Capital Exp. (TTM) (Millions $) 0

Business Description


Applied Therapeutics Inc is a biopharmaceutical company that focuses on developing and commercializing novel therapeutics for the treatment of serious diseases. The company aims to address unmet medical needs by targeting specific pathways to restore health and improve patient outcomes. Applied Therapeutics Inc utilizes a multi-disciplinary approach, combining expertise in drug development, clinical pharmacology, and translational medicine to advance its pipeline of therapeutic candidates. The company's research and development efforts primarily focus on therapies for glycobiology-related diseases, such as diabetic complications and rare genetic disorders.


   Company Address: 545 Fifth Avenue New York 10017 NY
   Company Phone Number: 220-9226   Stock Exchange / Ticker: NASDAQ APLT


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BMY   -5.59%    
JNJ   -3.26%    
LLY   -2.35%    
MRK   -4.83%    
TEVA   -3.2%    
VTRS   -5.47%    
• View Complete Report
   



Management Changes

Navigating Quality Challenges: Applied Therapeutics Appoints Industry Veteran Amid Significant Financial Losses

Published Tue, Jan 21 2025 12:00 PM UTC

In a strategic move aimed at bolstering its operational integrity, Applied Therapeutics Inc. has appointed Reena Thomas Colacot as Vice President and Head of Quality. Ms. Colacot arrives with over 25 years of quality leadership experience across the biopharmaceutical and medical device sectors, insights that are particularly crucial in light of the company s current financia...
Announcement

Securities and Science The Legal Crossroads of Applied Therapeutics, Inc.

Published Mon, Jan 6 2025 11:57 AM UTC

The realm of pharmaceutical investments often presents a delicate interplay between innovation and accountability. Recent legal developments concerning Applied Therapeutics, Inc. (NASDAQ: APLT) underscore the significant repercussions of corporate governance and transparency on investor trust and company performance. A series of class action lawsuits initiated against the co...
Announcement

Applied Therapeutics Under Scrutiny Investor Lawsuits Highlight Critical Phase III Trial Concerns

Published Wed, Dec 25 2024 9:00 PM UTC

The pharmaceutical landscape is often fraught with high stakes and heightened investor expectations, particularly when it comes to the development of new drugs. In late 2024, Applied Therapeutics, Inc. (NASDAQ: APLT), a company specializing in innovative treatments for serious diseases, found itself embroiled in legal challenges that have significant implications for its re...
Announcement

Investor Alert Key Deadlines in Applied Therapeutics Securities Class Action Highlighted by Rosen Law Firm

Published Thu, Dec 26 2024 1:35 AM UTC

In recent developments regarding Applied Therapeutics, Inc. (NASDAQ: APLT), legal counsel from the renowned Rosen Law Firm has issued an important reminder to investors concerning impending deadlines related to a securities class action. This update is pertinent for individuals who purchased securities of the biopharmaceutical company during the specified Class Period spanni...
Management Changes

Leadership Shift Amid Financial Turmoil: Applied Therapeutics Faces Investor Scrutiny and Legal Battles

Published Fri, Dec 20 2024 12:00 PM UTC

In an unexpected turn of events, Applied Therapeutics, Inc. has appointed John H. Johnson as Executive Chairman, a move that coincides with the departure of Shoshana Shendelman as CEO and the appointment of Les Funtleyder as interim Chief Executive Officer. This leadership reshuffling comes at a turbulent time for the biotech company, which has recently faced mounting financ...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 15.74
Price to Sales (Expected) -
Price to Book -
PEG (TTM) -

Financial Strength Current
Quick Ratio 0.36
Working Capital Ratio 0.96
Leverage Ratio (MRQ) -
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -0.11 $
Revenues (TTM) 0.01 $
Cash Flow (TTM) -
Cash 0.08 $
Book Value -
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 12,488
Net Income per Employee (TTM) -226,725
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) 0.02

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -1675.8 %
Net Margin (MRQ) -1899 %
Net Cash Flow Margin (MRQ) -1847.6 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Applied Therapeutics Inc's Segments





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.